Johnson & Johnson, another participant in the race to develop coronavirus vaccine, is all set to enter a late-stage human (clinical) trial for testing its vaccine for the most infectious disease in September, a company spokesperson has informed. Johnson & Johnson's phase 3 clinical trial of the coronavirus-vaccine would see the participation of nearly 60,000 healthy people, aged above 18.
Johnson & Johnson's coronavirus vaccine phase 3 human trials | What we know
- Johnson & Johnson COVID vaccine would enroll nearly 60,000 healthy people, will be conducted at 180 locations across the United States.
- Covid vaccine trial participants will be selected randomly.
- Participants who will receive a dose of a potential vaccine for coronavirus will be studied or observed by researchers for more than 2 years.
- Speaking to CNBC, J&J spokesman Jake Sargent has said that their phase 3 trials will be conducted at places having high incidence rates.
- Those the company is yet to entre phase 3 human trials, there is no information on when it will be ready for the use of common man, as the world is in a desperate need of a vaccine.
- There is no information yet about the price of Johnson & Johnson's coronavirus vaccine.
- Earlier, according to a study published in the journal Nature, Johnson & Johnson's vaccine trial results on monkeys were observed on the basis of the presence of the virus in the nasal swabs.
- Janssen's investigational vaccine elicited an immune response against SARS-CoV-2 in a preclinical, nonhuman study.
- Speaking on initial stage trials, Dr Paul Chief Scientific officer of J&J said, "this gives us confidence that we can test a single-shot vaccine in this epidemic and learn whether it has a protective effect in humans," HT quoted him as saying.
- J&J has begun early-stage human trials in the United States, Belgium.
